In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

The firm is prioritizing development of its anti-DKK1 antibody sirexatamab following promising Phase II results in microsatellite-stable colorectal cancer.

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results ...

Outlook Therapeutics, Inc.’s OTLK share price has dipped by 6.40%, which has investors questioning if this is right time to ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...